Wells Fargo’s Vertex Pharmaceuticals VRTX Stock Holding History

Wells Fargo’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-6,800	Closed	-$3.08M	–	7473
2025 Q4	$3.08M	Buy	+6,800	New	+$2.93M	﹤0.01%	3090
2024 Q4	–	Sell	-19,000	Closed	-$8.84M	–	7206
2024 Q3	$8.84M	Buy	+19,000	New	+$9.13M	﹤0.01%	1932
2024 Q2	–	Sell	-900	Closed	-$376K	–	7507
2024 Q1	$376K	Sell	900 -500	-36%	-$211K	﹤0.01%	4070
2023 Q4	$570K	Hold	1,400	–	–	﹤0.01%	3775
2023 Q3	$487K	Hold	1,400	–	–	﹤0.01%	3800
2023 Q2	$493K	Buy	+1,400	New	+$472K	﹤0.01%	3951
2021 Q3	–	Sell	-100,000	Closed	-$20.2M	–	7585
2021 Q2	$20.2M	Buy	+100,000	New	+$20.9M	﹤0.01%	1676
2016 Q1	–	Sell	-22,000	Closed	-$17K	–	6456
2015 Q4	$17K	Hold	22,000	–	–	﹤0.01%	5623
2015 Q3	$285K	Sell	22,000 -116,100	-84%	-$14.9M	﹤0.01%	4271
2015 Q2	$1.1M	Buy	138,100 +2,000	+1%	+$252K	﹤0.01%	3521
2015 Q1	$522K	Buy	+136,100	New	+$16.3M	﹤0.01%	3918

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Wells Fargo's VRTX Position: Q1 2026 in Review

Wells Fargo increased its Vertex Pharmaceuticals (VRTX) stake by 0.43% in Q1 2026, buying an estimated $1.48M and bringing the position to 744,995 shares worth $333M. The position accounts for 0.06% of the portfolio, ranked #266.

Wells Fargo first reported a position in VRTX in Q2 2013 and has held it in 52 quarters since. The position peaked at $443M in Q2 2020. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Wells Fargo held 744,995 shares of Vertex Pharmaceuticals worth $333M as of Q1 2026.
Wells Fargo bought 3,182 Vertex Pharmaceuticals shares in Q1 2026, an estimated $1.48M.
Vertex Pharmaceuticals made up 0.06% of Wells Fargo's portfolio in Q1 2026, its #266 holding.
Wells Fargo first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
Wells Fargo's Vertex Pharmaceuticals position peaked at $443M in Q2 2020.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.